Immix Biopharma Inc (IMMX): NEWS -PANCREATIC CANCER- Immix Biopharma...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Immix Biopharma Inc (IMMX)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	47
Posts	2202
Boards Moderated	0
Alias Born	10/04/2013

Re: None

Tuesday, 01/25/2022 10:39:33 PM

Tuesday, January 25, 2022 10:39:33 PM

NEWS -PANCREATIC CANCER- Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies

Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own pancreatic cancer and have an intact immune system.

Historically, 42-days is the median survival produced by a 4-drug combination: 2 chemotherapies and two immunotherapies in the same genetic pancreatic cancer mouse model.

"This data highlights why we are excited to collaborate with BeiGene on our planned 2022 Phase 1b/2a combination trial of IMX-110 + BeiGene anti-PD-1 tislelizumab in advanced solid tumors," said Ilya Rachman, CEO of ImmixBio. "We believe this upcoming combination clinical trial will allow us to expand into multiple oncology indications rapidly."

In 2022, the Company plans to commence combination IMX-110 + BeiGene Ltd (NASDAQ: BGNE) anti-PD-1 tislelizumab Phase 1b/2a clinical trial in advanced solid tumors.

Related: Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study.

The FDA has approved orphan drug designation for IMX-110 for soft tissue sarcoma. Additionally, the FDA has approved rare pediatric disease designation to IMX-110 for rhabdomyosarcoma.

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent IMMX News

Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 01:29:40 AM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 01:28:17 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:27:31 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/07/2024 10:15:34 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:09:52 PM
Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/05/2024 09:38:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:37:06 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2023 11:25:25 PM
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing • InvestorsHub NewsWire • 11/28/2023 03:48:59 PM
Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/10/2023 12:57:06 AM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/25/2023 08:15:53 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 11:03:32 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/15/2023 10:27:44 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2023 08:58:37 PM
Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 08/30/2023 08:15:02 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2023 08:28:40 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2023 08:05:32 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:15:45 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:15:42 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:15:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2023 08:15:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:30:37 PM

More IMMX News

InvestorsHub NewsWire

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONG • May 17, 2024 11:00 AM

VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM

ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM

Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM

Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow